Free tool
FAERS Monitor: Marcaine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018692 or its brand name (Marcaine, Bupivacaine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
4,689
Serious
2,689
57% of reports
Hospitalization
1,124
Death reported
313
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,616
- anaesthetic complication283
- off label use246
- pain219
- hypoaesthesia209
- maternal exposure during pregnancy209
- hypotension199
- headache177
- dyspnoea168
- dizziness154
- nausea145
- condition aggravated143
- fatigue142
- hypertension142
- vomiting133
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 91 |
| 2005 | 77 |
| 2006 | 97 |
| 2007 | 65 |
| 2008 | 80 |
| 2009 | 115 |
| 2010 | 86 |
| 2011 | 100 |
| 2012 | 92 |
| 2013 | 98 |
| 2014 | 122 |
| 2015 | 191 |
| 2016 | 617 |
| 2017 | 385 |
| 2018 | 244 |
| 2019 | 240 |
| 2020 | 239 |
| 2021 | 194 |
| 2022 | 401 |
| 2023 | 251 |
| 2024 | 325 |
| 2025 | 333 |
| 2026 | 246 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,470 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaesthetic complicationSignal | 283 | 528.2 | 468.6 | 132,793 |
| maternal exposure during pregnancySignal | 209 | 10.5 | 9.2 | 1,799 |
| hypoaesthesiaSignal | 209 | 6.3 | 5.5 | 926 |
| drug ineffectiveSignal | 1,616 | 5.5 | 5.3 | 6,344 |
| hypotensionSignal | 199 | 4.5 | 3.9 | 534 |
| hypertensionSignal | 142 | 3.0 | 2.6 | 190 |
| condition aggravatedSignal | 143 | 2.1 | 1.8 | 84 |
| pain | 219 | 1.6 | 1.4 | 50 |
| dizziness | 154 | 1.4 | 1.2 | 16 |
| dyspnoea | 168 | 1.3 | 1.1 | 14 |
| vomiting | 133 | 1.3 | 1.1 | 7 |
| headache | 177 | 1.3 | 1.1 | 10 |
| off label use | 246 | 1.3 | 1.1 | 14 |
| nausea | 145 | 0.8 | 0.7 | 6 |
| fatigue | 142 | 0.8 | 0.7 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.